Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centre Oscar Lambret
OBJECTIVES:
Primary
* Evaluate the validity of determining CA 15-3 levels in the cerebrospinal fluid (CSF) using automated immuno-enzymatic methods.
Secondary
* Determine the sensitivity and specificity of these assays in assessing CA 15-3 in CSF.
* Assess favorability of intrathecal production of CA 15-3.
* Determine threshold interpretations of CA 15-3 levels in CSF.
OUTLINE: This is a multicenter study.
Within 15 days of suspected meningeal involvement, blood and cerebrospinal fluid samples are collected. Samples are examined by immunoenzyme assays. Patients with suspected cases of carcinomatous meningitis undergo cerebrospinal MRI.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
DISEASE CHARACTERISTICS:
Meets 1 of the following criteria:
* Diagnosis of metastatic breast cancer with evidence suggestive of carcinomatous meningitis, with or without brain metastasis
* Other type of cancer with evidence suggestive of carcinomatous meningitis
* Meningeal syndrome without context of cancer
PATIENT CHARACTERISTICS:
No other prior cancers
Not pregnant or nursing
PRIOR CONCURRENT THERAPY:
No prior intrathecal treatment
At least 4 weeks since prior interferon
No concurrent participation in another clinical trial
Clareo Health | Study of Cerebrospinal Fluid Samples in Diagnosing Carcinomatous Meningitis in Patients With Cancer or Meningeal Syndrome
